Feb 25 (Reuters) - Contract drug manufacturer Thermo
Fisher Scientific ( TMO ) said on Tuesday it will buy
Solventum's ( SOLV ) purification and filtration business for
about $4.1 billion in cash.
The transaction is expected to be completed by the end of
2025.